Almost a third of outpatients with chronic coronary artery disease (CAD) report having angina in the prior month, which is frequently under-recognized by their cardiologists. Whether under-recognition is associated with less treatment escalation to control angina, and potential underuse of treatment, is unknown.
Introduction
Among patients with coronary artery disease (CAD), angina is not only common 1 but also can adversely affect patient's quality of life. 2, 3 Consequently, eliminating angina and improving quality of life are primary treatment goals for the outpatient management of stable CAD. 4 Treatment of angina can be achieved through multiple modalities including medications 4 -8 and revascularization. 3,9 -13 Even among patients with continued angina despite maximal medical therapy and whose anatomy is not amenable to revascularization, options for treatment exist in the form of spinal cord stimulation, 14 enhanced external counter pulsation, 15, 16 and other novel strategies. 14,17 -19 However, in order to select the appropriate treatment plan for the patient, the physician must first appropriately recognize the patient's angina burden.
Due to the inherent limitations of history taking, and the time constraints of patients and physicians, appropriate recognition of angina can be challenging. 20 In a recent study of patients with CAD and angina, we found that 42% of patients reported more frequent angina than the cardiologists estimated that they had experienced, with substantial variability in the under-recognition rate across providers (0 -85%). 21 While this high rate of under-recognition of angina among outpatients with CAD is concerning, the clinical implications are unknown.
We hypothesized that if physicians under-recognized the frequency of patients' angina, they would be less likely to intensify antianginal treatment. As such, we examined factors that are associated with treatment escalation (either intensification of antianginal medications or referral for diagnostic or invasive testing) and, specifically, whether under-recognition of angina was associated with a lack of treatment escalation. Finding evidence of a lack of treatment escalation among patients with under-recognized angina could suggest missed opportunities to improve patients' health status and underuse of potentially beneficially therapies. It would also support the use of standardized, patient-reported assessments for angina among outpatients with CAD as a potential strategy to minimize underrecognition in routine clinical practice.
Methods

Study design and population
The Angina Prevalence and Provider Evaluation of Angina Relief (AP-PEAR) study was a cross-sectional, observational study designed to assess angina and its effect on quality of life in outpatients with CAD. The 25 participating sites were identified from US cardiology outpatient practices participating in the PINNACLE Registry (a national registry sponsored by the American College of Cardiology). For 1 -2 weeks of active enrolment per site, between April 2013 and July 2015, local study coordinators recruited 50 -75 consecutive adults with a history of CAD; defined as a diagnosis of stable angina, prior myocardial infarction, prior percutaneous coronary intervention (PCI), or prior coronary artery bypass graft surgery. Sites were instructed to enrol consecutive patients with CAD, regardless of the reason for their clinic visit. Eligible patients included those ≥18 years of age who had at least one prior office visit to the practice. Patients with dementia, those unable to speak or read English, and prisoners were excluded. Each participating site obtained Institutional Research Board approval, which allowed for a waiver of written informed consent at all sites, except one where patients provided written informed consent.
Assessment of angina and definition of under-recognition
A unique feature of angina is that laboratory and imaging tests cannot measure it. As such, there is no 'gold standard' to capture patients' experiences. 22 Patient-reported symptoms of angina are strongly associated with patients' quality of life, 23 are predictive of hospitalizations for acute coronary syndromes and mortality, 24 and are strong drivers of healthcare utilization. 25 Thus, we believe angina is a symptom experienced by the patient and best reported by the patient. Accordingly, enrolled patients were asked immediately prior to their cardiologist visit to complete the Seattle Angina Questionnaire (SAQ). The SAQ is a selfadministered, reliable, and valid 19-item questionnaire with a 4-week recall period that measures five domains of health in patients with CAD: Angina Frequency (SAQ AF), Angina Stability, Quality of Life, Physical Limitation, and Treatment Satisfaction. 26, 27 Additionally, the SAQ Summary Scale combines the three domains of symptoms, function, and quality of life, in order to integrate the multiple SAQ domains into a single score. 28 Individual domain scores and the Summary Score range from 0 to 100, with higher scores indicating fewer symptoms and better quality of life. The SAQ has undergone extensive reliability and validity testing 27, 28 and is associated with long-term survival, hospitalization for acute coronary syndromes, and increased healthcare utilization among patients with chronic CAD. 25 The frequency of angina from the patients' perspective is captured with the SAQ AF domain, which has been shown to correlate closely with daily angina diaries. 29 Congruent with prior work, angina was categorized as none (SAQ AF score ¼ 100), monthly (SAQ AF score ¼ 61-99), weekly (SAQ AF score ¼ 31-60), and daily (SAQ AF score ¼ 0-30). 30 For the purposes of this study, we excluded patients who reported having no angina in the 4 weeks prior to their clinic visit (SAQ AF ¼ 100), as we were interested in investigating the patterns of treatment escalation among patients with chest pain.
Without access to patients' SAQ questionnaires, and immediately after the visit, providers were asked whether the patient had any chest pain in the prior month and, if so, how often the chest pain occurred [daily, weekly, monthly, or less than monthly (less than monthly was considered the same as monthly, for this analysis)]. Under-recognition of angina was defined as the physician reporting a lower frequency of angina frequency than the patient had reported using the SAQ domain (e.g. the patient reported weekly angina and the physician estimated monthly or no symptoms). As patients with correctly recognized and over-recognized angina had similar rates of treatment escalation (P ¼ 0.23), they were considered to be a single group.
Treatment escalation
Providers were asked at the end of the visit to specify their CAD treatment plan based on this particular visit. Any of the following were considered treatment escalation: (i) intensification of antianginal medications (increase in dose or addition of a new medication); (ii) ordering a stress test, coronary computed tomography angiography, coronary angiography, or revascularization (PCI or bypass graft surgery); or (iii) hospital admission. Antianginal medications (including doses and frequencies) were recorded at the beginning and end of each clinic visit and included b-blockers, calcium channel blockers, long-acting nitrates, and ranolazine.
Statistical methods
The primary goal of our study was to examine predictors of treatment escalation among patients with CAD and angina and, specifically, whether under-recognition of the patient's angina was associated with treatment escalation by the physician. A secondary aim is to study the variability of treatment escalation among physicians. Demographic and clinical characteristics were compared between patients who did and did not receive treatment escalation using independent t-tests for continuous variables and x 2 tests for categorical variables. To study predictors of treatment escalation, we constructed a hierarchical multivariable logistic regression model in which both site and physician were included as random effects, to account for the clustering of patients within physicians and within sites. In addition to under-recognition of angina, we included a number of variables that could be expected to be associated with treatment escalation. Variables were selected a priori based on literature review and clinical judgement (balanced against concerns of over-fitting) and included the following: age, sex, race (white vs. nonwhite), self-reported avoiding care due to cost, history of coronary artery bypass graft surgery, SAQ Summary Score, SAQ Angina Stability domain (which is not included in the SAQ Summary Score and reflects recent changes in patients' angina), being on ≥2 antianginal medications on arrival to clinic (to account for aggressive antianginal therapy), and provider specialty (interventional vs. non-interventional cardiology). Variability among physicians was explored with a median odds ratio, which estimates the average relative difference in two hypothetically identical patients receiving treatment escalation if seen by two different physicians. For example, median odds ratio of 1 suggests no physician-level variation Under-recognition of angina and treatment in treatment escalation, while an MOR of 2 suggests a two-fold difference in the odds of receiving treatment escalation if two random physicians see an identical patient. All data were complete for the patients in the analytic cohort. All statistical analyses were performed with SAS, version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient characteristics
Of 1257 patients with CAD enrolled in APPEAR, evaluated by 155 cardiologists, 411 (32.7%) reported some angina in the prior month and were included in this study. Mean age of patients was 69.0 years, 60.3% were male, and 91.4% were white. Cardiac and non-cardiac co-morbidities were typical of US patients with chronic CAD, with diabetes in 38.2%, hypertension in 80.0%, a history of PCI in 57.2%, a history of myocardial infarction in 38.2%, and a history of coronary artery bypass grafting in 31.6%. Among these patients who all had some angina, most reported monthly symptoms (76.6%), with 18.7% reporting weekly angina and 4.6% reporting daily angina.
Frequency of treatment escalation
Among the 411 patients with CAD who reported angina in the prior month, 106 (25.8%) patients had their treatment escalated at the end of their visit, of whom 29 (27.3%) were managed with uptitration or addition of antianginal medications, 66 (62.2%) with diagnostic/invasive testing, and 11 (10.4%) with both. The most common pharmacological strategy was prescribing/up-titrating long-acting nitrates followed by prescribing/up-titrating b-blocker therapy (see Supplementary material online, Table S1 ). The most commonly used diagnostic/invasive evaluation was stress testing, followed by referral for coronary angiography (see Supplementary material online, Table S2 ). Table 1 shows the demographic and clinical characteristics of the patients stratified by whether the patient received treatment escalation or not. Patients whose treatment was escalated by their physicians were less likely to have a history of myocardial infarction (escalation vs. no escalation: 29.2 vs. 41.3%, P ¼ 0.027) and reported lower (worse) disease-specific health status across most of the SAQ domains and the Summary Score.
Association of under-recognition of angina with treatment escalation
Of the 411 patients who reported angina in the prior month, 178 (43.3%) patients were under-recognized by their provider, 88 (21.4%) were correctly recognized, and 145 (35.2%) were believed to have had more angina by physicians than the patients reported. Rates of treatment escalation were similar between patients whose physicians over-estimated their angina (34.1 vs. 42.1%, P ¼ 0.23), and thus these two groups were combined into a single group of patients with appropriately recognized angina. Patients with under-recognized angina were less likely to get treatment escalation compared with patients whose angina was appropriately recognized (8.4 vs. 39.1%, P ¼ ,0.001), and this discrepancy persisted regardless of whether the patient reported daily, weekly, or monthly symptoms ( Figure 1 ; see Supplementary material online, Table S3 ). For example, among patients with daily angina, only 12.5% of patients with under-recognized daily angina received treatment escalation, when compared with 54.6% of patients whose daily angina was appropriately recognized (P , 0.001). In the hierarchical multivariable model that adjusted for demographic and clinical characteristics of the patients (including severity and acceleration of angina), under-recognition continued to be strongly associated with lack of treatment escalation (adjusted OR 0.10, 95% CI 0.04-0.21, P , 0.001) ( Table 2 ). In unadjusted analysis, there was substantial variability in the percentage of patients with angina who received treatment escalation and the use of particular treatment strategies (Figure 2) . Overall rates of treatment escalation ranged from 6.4 to 53.8%, with a greater reliance on referral for diagnostic or invasive testing for many sites. After adjusting for clinical characteristics and physicians' under-recognition rates, the median odds ratio for variability across physicians was 1.96 (P ¼ 0.010), indicating that the odds ratio of treatment escalation varies, on average, two-fold between two randomly selected physicians seeing statistically similar patients.
Other factors associated with treatment escalation
Discussion
While most investigations on the appropriateness of care in coronary disease have focused on overuse of diagnostic tests and procedures, 31 -35 few have examined underuse of treatment. 36 We have previously demonstrated that angina is common in patients with stable CAD and often under-recognized. 37, 38 In this study, we extend our prior work by demonstrating that under-recognition is the factor most strongly associated with not intensifying therapy among patients with angina. Although this association might seem obvious, this is the first multi-center prospective study, to our knowledge, to document the strength of this association, which we believe is striking (i.e. a 10-fold decreased odds of treatment escalation among patients who were under-recognized), and to identify a possible mechanism for the underuse of antianginal strategies. These novel data underscore the importance of testing the implementation of patient-centered outcome measures into routine clinical care to help recognize and quantify patients' angina as a foundation for improving the consistency and quality of care of patients with chronic coronary disease and angina.
The aggressive treatment of angina is a cornerstone of managing patients with coronary disease. Patient-reported chest discomfort is strongly associated with worse health status, more frequent hospitalizations, and increased healthcare spending. 25, 30 Treatment with antianginal medications or revascularization is known to relieve symptoms and improve quality of life. 3,5 -8 In fact, the magnitude of reduction in angina is the factor most strongly associated with the quality of life benefits from PCI. 30 Beyond these traditional treatments, there are additional options for those who continue to have angina despite optimal medical therapy and revascularization. 14 -19 Despite the detrimental effects of frequent angina in patients and the availability of multiple treatment options to improve these symptoms, we found here that whether or not a patient received treatment escalation for their angina did not depend on the patient's clinical history or severity of angina but whether or not the patient's physician appropriately recognized the patient's angina. Patients whose angina was under-recognized were 10 times less likely to be referred for diagnostic or invasive testing or have their antianginal medications intensified compared with patients whose angina was appropriately recognized. We also found that two-thirds of patients with daily or weekly angina who were on ,2 antianginal medications (considered to be minimal treatment by the Appropriate Use Criteria 32 ) were discharged from clinic with unchanged treatment plans. It is important to note that we make no assumption as to what the 'correct' level of treatment escalation should be. However, what we believe is the central message of our study is that there should not be such a discrepancy between rates of treatment escalation simply based on the recognition of angina. In other words, if the 'appropriate' rate of treatment escalation is 50% when the angina is recognized accurately and we observe an adjusted 90% lower rate of treatment escalation when the angina is not accurately recognized, then there are probably missed opportunities for escalating treatment that could represent under-treatment.
Given the frequency with which under-recognition occurs in busy cardiology outpatient practices and the clinical implications of this under-recognition, these findings support instituting a patient-centered tool for quantifying the burden of patients' angina to facilitate assessment by providers in order to make appropriate treatment and testing recommendations. For example, the SAQ-7 28 is a convenient, short, validated, patient-centered tool that could be used to accurately capture patients' angina, when compared with daily diaries. 29 The SAQ-7 can be self-administered before the clinic visit, integrated into the electronic medical record, and reviewed by the physician even before entering the exam room, providing a feasible strategy to improve physicians' awareness of patients' angina. Such an approach, analogous to a standardized history of patients' symptoms, could also save time in a busy outpatient clinic and serve as a 'vital sign' in the management of patients' angina. Such a strategy would also be well aligned with the goals of the Centers for Medicare & Medicaid Services in promoting and implementing patient-reported outcome measures to improve the overall quality of care. 39 Further studies are needed to understand the effect of these patient-administered tools on both the effectiveness of patient -physician communication and clinical outcomes.
Our study findings should be interpreted with the following limitations. First, although this is a multi-center study from a large number of cardiology outpatient practices around the USA, it is unknown if the findings are generalizable. Second, APPEAR was a cross-sectional study. While we showed that under-recognition of angina was strongly associated with a lack of treatment escalation, we were unable to examine whether these differences in treatment escalation led to differences in health status or other clinical outcomes over time. Other studies are needed to examine the longterm impact of angina under-recognition. Third, the SAQ was completed by patients' right before the clinic visit, which could have made the patients more aware of their symptoms, thereby improving their communication with the physicians. In addition, physicians were aware of the study and that they would be asked to estimate the patient's chest pain and their treatment recommendations. As such, we expect that our findings represent the best-case scenario, and the rates of under-recognition and variability in treatment escalation likely would be higher outside of the confines of a structured study. Alternatively, it is possible that patients believed their physicians would see the SAQ and therefore did not fully report their symptoms. Finally, due to the number of events, we were unable to consider all potential clinical and demographic factors that could be associated with treatment escalation in the model. While we selected the covariates based on clinical judgement and prior literature, it is possible that an important covariate was excluded from the model. Nevertheless, given the strength of the association between under-recognition and treatment escalation, it is unlikely that any additional variable would have materially changed the significance of the identified association.
In conclusion, we found that among patients with CAD and angina in US cardiology outpatient practices, 26% of patients had their antianginal medications intensified or were referred for diagnostic or invasive testing. However, this rate varied substantially based on whether or not the physician accurately assessed the frequency of the patient's angina. Further studies are needed to understand the long-term implications of angina under-recognition on health status and other clinical outcomes. Furthermore, studies are needed to test and implement systems that employ health status tools, such as the SAQ-7, that can objectively assess angina from the patient's perspective and create the ability to readily communicate these data to the physician at the time of treatment.
